• Western blot analysis of various lysates using ASB17 Rabbit polyclonal antibody (STJ119846) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (STJS000856) at 1:10000 dilution. Lysates/proteins: 25 Mu g per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 30s.

Anti-ASB17 antibody (30-130) (STJ119846)

SKU:
STJ119846

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: WB
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-ASB17 (30-130) is suitable for use in Western Blot research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3.
Purification: Affinity purification
Dilution Range: WB 1:500-1:2000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: ASB17
Gene ID: 127247
Uniprot ID: ASB17_HUMAN
Immunogen Region: 30-130
Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 30-130 of human ASB17 (NP_543144.1).
Immunogen Sequence: PSLQFLGQWGYHCYEPRIYR SLAKILRYVDLDGFDALLTD YIAFVEKSGYRFEVSFNLDF TEICVNTILYWVFARKGNPD FVELLLKKTKDYVQDRSCNL A
Tissue Specificity Specifically expressed in testis. Not detected in other tissues tested.
Function May be a substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.
Protein Name Ankyrin Repeat And Socs Box Protein 17
Asb-17
Database Links Reactome: R-HSA-8951664
Reactome: R-HSA-983168
Alternative Antibody Names Anti-Ankyrin Repeat And Socs Box Protein 17 antibody
Anti-Asb-17 antibody
Anti-ASB17 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance